Gain Therapeutics
NASDAQ: GANX3 known investors
Gain Therapeutics develops small molecule drugs for neurodegenerative diseases using an AI-powered drug discovery platform that identifies novel binding sites on disease-related proteins. The company's lead candidate, rexaceract, targets GBA-Parkinson's disease and is in Phase I clinical trials.